AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZLAB
  4. [Form 4] Zai Lab Limited American Insider Trading Activity

[Form 4] Zai Lab Limited American Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Chen Yajing, Chief Financial Officer of Zai Lab Ltd (ZLAB), reported a sale of 4,096 American Depositary Shares (ADSs) on 08/08/2025. Each ADS represents ten ordinary shares, and the ADSs are fully fungible with ordinary shares. The reported sale price was $34.01 per ADS and the transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2025. Following this disposition the reporting person beneficially owned 16,908 ADSs. The Form 4 discloses no derivative transactions and was signed by an attorney-in-fact on behalf of the reporting person.

Chen Yajing, Chief Financial Officer di Zai Lab Ltd (ZLAB), ha comunicato la vendita di 4,096 American Depositary Shares (ADS) in data 08/08/2025. Ciascun ADS rappresenta dieci azioni ordinarie e gli ADS sono pienamente fungibili con le azioni ordinarie. Il prezzo di vendita dichiarato 猫 stato $34.01 per ADS e l'operazione 猫 stata eseguita in base a un piano di negoziazione preesistente Rule 10b5-1 adottato dal dichiarante il 3 marzo 2025. Dopo questa cessione, il dichiarante deteneva beneficiariamente 16,908 ADS. Il Modulo 4 non segnala transazioni su derivati ed 猫 stato firmato da un procuratore che ha agito per conto del dichiarante.

Chen Yajing, Chief Financial Officer de Zai Lab Ltd (ZLAB), inform贸 la venta de 4,096 American Depositary Shares (ADS) el 08/08/2025. Cada ADS representa diez acciones ordinarias, y los ADS son totalmente fungibles con las acciones ordinarias. El precio de venta informado fue de $34.01 por ADS y la transacci贸n se realiz贸 conforme a un plan de negociaci贸n preexistente Rule 10b5-1 adoptado por la persona informante el 3 de marzo de 2025. Tras esta disposici贸n, la persona informante pose铆a beneficiariamente 16,908 ADS. El Formulario 4 no revela operaciones derivadas y fue firmado por un apoderado en nombre de la persona informante.

Chen Yajing雼橃潃 Zai Lab Ltd (ZLAB)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)搿滌劀 2025/08/08鞐� 4,096臧滌潣 American Depositary Shares(ADS)毳� 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 臧� ADS電� 氤错喌欤� 10欤�毳� 雮橅儉雮措┌ ADS電� 氤错喌欤检檧 鞕勳爠頌� 靸來樃甑愴櫂 臧�電ロ暕雼堧嫟. 鞁犼碃霅� 毵る弰臧�瓴╈潃 ADS雼� $34.01鞚措┌, 頃措嫻 瓯半灅電� 氤搓碃鞚胳澊 2025雲� 3鞗� 3鞚�鞐� 毂勴儩頃� 靷爠 靹れ爼霅� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 歆戫枆霅橃棃鞀惦媹雼�. 鞚� 觳橂秳 鞚错泟 氤搓碃鞚胳潃 16,908 ADS毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. Form 4鞐愲姅 韺岇儩靸來拡 瓯半灅臧� 鞐嗢溂氅�, 氤搓碃鞚胳潉 雽�鞁犿晿鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.

Chen Yajing, directrice financi猫re (Chief Financial Officer) de Zai Lab Ltd (ZLAB), a d茅clar茅 la vente de 4 096 American Depositary Shares (ADS) le 08/08/2025. Chaque ADS repr茅sente dix actions ordinaires et les ADS sont enti猫rement fongibles avec les actions ordinaires. Le prix de vente d茅clar茅 茅tait de 34,01 $ par ADS et la transaction a 茅t茅 effectu茅e conform茅ment 脿 un plan de n茅gociation Rule 10b5-1 pr茅existant adopt茅 par la personne d茅clarante le 3 mars 2025. 脌 la suite de cette cession, la personne d茅clarante d茅tenait b茅n茅ficiairement 16 908 ADS. Le Formulaire 4 ne mentionne aucune op茅ration sur d茅riv茅s et a 茅t茅 sign茅 par un mandataire au nom de la personne d茅clarante.

Chen Yajing, Chief Financial Officer von Zai Lab Ltd (ZLAB), meldete den Verkauf von 4.096 American Depositary Shares (ADS) am 08.08.2025. Jede ADS entspricht zehn Stammaktien, und die ADS sind voll fungibel mit den Stammaktien. Der gemeldete Verkaufspreis betrug $34,01 je ADS, und die Transaktion erfolgte im Rahmen eines bereits bestehenden Rule-10b5-1-Handelsplans, der von der meldenden Person am 3. M盲rz 2025 beschlossen wurde. Nach dieser Ver盲u脽erung hielt die meldende Person wirtschaftlich 16.908 ADS. Das Formular 4 weist keine Derivatgesch盲fte aus und wurde von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.

Positive
  • Transaction executed under a Rule 10b5-1 trading plan, indicating the sale followed a pre-established compliance arrangement
  • Clear disclosure of holdings after the sale: reporting person beneficially owned 16,908 ADSs following the transaction
  • No derivative transactions reported, limiting complexity of insider exposure disclosed
Negative
  • Officer disposition of 4,096 ADSs reduces the reporting person's direct beneficial holdings
  • Insider sale reported may be interpreted by some market participants as a decrease in insider ownership

Insights

TL;DR: CFO sold 4,096 ADSs under a 10b5-1 plan; beneficial ownership now 16,908 ADSs鈥攔outine insider disposition.

The sale of 4,096 ADSs at $34.01 on 08/08/2025 was executed under a Rule 10b5-1 plan adopted March 3, 2025, which indicates the transaction followed a pre-established schedule rather than a discretionary trade. The Form 4 reports only a non-derivative sale and the remaining direct beneficial ownership of 16,908 ADSs. For investors, this is a transparent insider disposition; the filing provides clear transactional terms but does not signal operational or financial changes at the company.

TL;DR: Transaction adheres to compliance protocols; attorney-in-fact signature and 10b5-1 adoption date are disclosed.

The Form 4 includes governance-relevant details: the 10b5-1 plan adoption date (March 3, 2025) and the attorney-in-fact signature on the filing. These elements support procedural compliance with insider-trading rules and improve disclosure quality. No derivative positions or amendments are reported, and the filing records a straightforward sale by an officer rather than any change in board composition or company policies.

Chen Yajing, Chief Financial Officer di Zai Lab Ltd (ZLAB), ha comunicato la vendita di 4,096 American Depositary Shares (ADS) in data 08/08/2025. Ciascun ADS rappresenta dieci azioni ordinarie e gli ADS sono pienamente fungibili con le azioni ordinarie. Il prezzo di vendita dichiarato 猫 stato $34.01 per ADS e l'operazione 猫 stata eseguita in base a un piano di negoziazione preesistente Rule 10b5-1 adottato dal dichiarante il 3 marzo 2025. Dopo questa cessione, il dichiarante deteneva beneficiariamente 16,908 ADS. Il Modulo 4 non segnala transazioni su derivati ed 猫 stato firmato da un procuratore che ha agito per conto del dichiarante.

Chen Yajing, Chief Financial Officer de Zai Lab Ltd (ZLAB), inform贸 la venta de 4,096 American Depositary Shares (ADS) el 08/08/2025. Cada ADS representa diez acciones ordinarias, y los ADS son totalmente fungibles con las acciones ordinarias. El precio de venta informado fue de $34.01 por ADS y la transacci贸n se realiz贸 conforme a un plan de negociaci贸n preexistente Rule 10b5-1 adoptado por la persona informante el 3 de marzo de 2025. Tras esta disposici贸n, la persona informante pose铆a beneficiariamente 16,908 ADS. El Formulario 4 no revela operaciones derivadas y fue firmado por un apoderado en nombre de la persona informante.

Chen Yajing雼橃潃 Zai Lab Ltd (ZLAB)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)搿滌劀 2025/08/08鞐� 4,096臧滌潣 American Depositary Shares(ADS)毳� 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 臧� ADS電� 氤错喌欤� 10欤�毳� 雮橅儉雮措┌ ADS電� 氤错喌欤检檧 鞕勳爠頌� 靸來樃甑愴櫂 臧�電ロ暕雼堧嫟. 鞁犼碃霅� 毵る弰臧�瓴╈潃 ADS雼� $34.01鞚措┌, 頃措嫻 瓯半灅電� 氤搓碃鞚胳澊 2025雲� 3鞗� 3鞚�鞐� 毂勴儩頃� 靷爠 靹れ爼霅� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 歆戫枆霅橃棃鞀惦媹雼�. 鞚� 觳橂秳 鞚错泟 氤搓碃鞚胳潃 16,908 ADS毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. Form 4鞐愲姅 韺岇儩靸來拡 瓯半灅臧� 鞐嗢溂氅�, 氤搓碃鞚胳潉 雽�鞁犿晿鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.

Chen Yajing, directrice financi猫re (Chief Financial Officer) de Zai Lab Ltd (ZLAB), a d茅clar茅 la vente de 4 096 American Depositary Shares (ADS) le 08/08/2025. Chaque ADS repr茅sente dix actions ordinaires et les ADS sont enti猫rement fongibles avec les actions ordinaires. Le prix de vente d茅clar茅 茅tait de 34,01 $ par ADS et la transaction a 茅t茅 effectu茅e conform茅ment 脿 un plan de n茅gociation Rule 10b5-1 pr茅existant adopt茅 par la personne d茅clarante le 3 mars 2025. 脌 la suite de cette cession, la personne d茅clarante d茅tenait b茅n茅ficiairement 16 908 ADS. Le Formulaire 4 ne mentionne aucune op茅ration sur d茅riv茅s et a 茅t茅 sign茅 par un mandataire au nom de la personne d茅clarante.

Chen Yajing, Chief Financial Officer von Zai Lab Ltd (ZLAB), meldete den Verkauf von 4.096 American Depositary Shares (ADS) am 08.08.2025. Jede ADS entspricht zehn Stammaktien, und die ADS sind voll fungibel mit den Stammaktien. Der gemeldete Verkaufspreis betrug $34,01 je ADS, und die Transaktion erfolgte im Rahmen eines bereits bestehenden Rule-10b5-1-Handelsplans, der von der meldenden Person am 3. M盲rz 2025 beschlossen wurde. Nach dieser Ver盲u脽erung hielt die meldende Person wirtschaftlich 16.908 ADS. Das Formular 4 weist keine Derivatgesch盲fte aus und wurde von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chen Yajing
(Last) (First) (Middle)
C/O ZAI LAB LIMITED
314 MAIN STREET, 4TH FLOOR, SUITE 100
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares(1) 08/08/2025 S(2) 4,096 D $34.01 16,908 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.
/s/ Bruce Blefeld, Attorney-in-Fact 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Zai Lab (ZLAB) insider Chen Yajing sell?

The filing shows Chen Yajing sold 4,096 ADSs on 08/08/2025 at a price of $34.01 per ADS.

Was the sale part of an authorized trading plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2025.

How many ADSs does the reporting person own after the sale?

Following the reported transaction the reporting person beneficially owned 16,908 ADSs.

Did the Form 4 report any derivative securities?

No. Table II contains no entries; the Form 4 reports only a non-derivative sale of ADSs.

Who signed the Form 4 and when?

The Form 4 was signed by /s/ Bruce Blefeld, Attorney-in-Fact on 08/12/2025.
Stock ZLAB logo
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

#1524 Ranked by Market Cap
N/A Ranked by Dividends

ZLAB Latest News

Aug 13, 2025
Zai Lab Establishes Oncology Scientific Advisory Board
Aug 7, 2025
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
Jul 10, 2025
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
Jun 30, 2025
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Jun 13, 2025
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

ZLAB Latest SEC Filings

Aug 13, 2025
[144] Zai Lab Limited American SEC Filing
Aug 12, 2025
[Form 4] Zai Lab Limited American Insider Trading Activity
Aug 12, 2025
[Form 4] Zai Lab Limited American Insider Trading Activity
Aug 12, 2025
[144] Zai Lab Limited American SEC Filing
Aug 12, 2025
[SCHEDULE 13G/A] Zai Lab Limited American SEC Filing

ZLAB Stock Data

3.81B
106.54M
1.42%
50.94%
3.61%
Biotechnology
Pharmaceutical Preparations
China
SHANGHAI